Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881763 · ClinicalTrials.gov registry record · Phase 4
Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
A Phase 4 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT01881763 is a Phase 4 study that has completed, run by Northwell Health. The registered enrollment target is 31 participants.
The verdict
NCT01881763, a Phase 4 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The study aims to compare outcomes of Electroconvulsive Therapy (ECT) using ketamine versus methohexital anesthesia in depressed patients. The investigators hypothesize that patients who receive ketamine anesthesia during ECT will achieve remission status faster than those receiving methohexital anesthesia. Also, at the end of the ECT course subjects will display fewer cognitive side effects compared to those treated with methohexital anesthesia.
Interventions
- DRUG Ketamine
- DRUG Methohexital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881763
The ClinicalTrials.gov registry entry for NCT01881763 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01881763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01881763 about?
NCT01881763 is a clinical study titled "Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression". The study aims to compare outcomes of Electroconvulsive Therapy (ECT) using ketamine versus methohexital anesthesia in depressed patients. The investigators hypothesize that patients who receive ketamine anesthesia during ECT will achieve remission status faster than those receiving methohexital ane...
What is the current status of trial NCT01881763?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2010-06. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01881763?
The interventions under investigation include: Ketamine (DRUG), Methohexital (DRUG).
Who is sponsoring clinical trial NCT01881763?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.